<DOC>
	<DOCNO>NCT02803203</DOCNO>
	<brief_summary>The purpose study test safety combine drug osimertinib bevacizumab different dose level . The investigator want find effect , good and/or bad , take osimertinib bevacizumab patient lung cancer . This study try find best dose osimertinib bevacizumab give together cause significant side effect . Once investigator determine combine osimertinib bevacizumab safe , want see combination effective treating lung cancer EGFR mutation .</brief_summary>
	<brief_title>Osimertinib Bevacizumab Treatment EGFR-mutant Lung Cancers</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Osimertinib</mesh_term>
	<criteria>Written inform consent Advanced biopsyproven metastatic nonsmall cell lung cancer Somatic activate mutation EGFR No prior treatment EGFR TKI No prior treatment VEGF inhibitor Measurable ( RECIST 1.1 ) indicator lesion previously irradiate Karnofsky performance status ( KPS ) ≥ 70 % Age &gt; 18 year old Adequate organ function AST , ALT ≤ 3 x ULN Total bilirubin ≤ 1.5x ULN Creatinine ≤ 1.5x ULN OR calculate creatinine clearance &gt; 60ml/min Absolute neutrophil count ( ANC ) ≥ 1000 cells/mm3 Hemoglobin≥8.0 g/dL Platelets ≥100,000/mm3 Any contraindication bevacizumab include limited recent 1 . Any previous venous thromboembolism &gt; NCI CTCAE Grade 3 2 . Severe uncontrolled hypertension ( systolic blood pressure ≥150 mmHg and/or diastolic blood pressure ≥ 100mmHg ) 3 . Cardiovascular disease include stroke myocardial infarction &lt; 6 month prior study enrollment , New York Heart Association Grade 2 great congestive heart failure , serious cardiac arrythmia uncontrolled medication 4 . Hemorrhagic brain metastasis . Asymptomatic ( require escalate dos steroid ) brain metastasis acceptable . 5 . History severe proteinuria ( urine dipstick ≥ 2+ 24 hr urine &gt; 2gm/24hr ) 6 . Prior history hypertensive crisis hypertensive encephalopathy 7 . History central nervous system disease ( e.g . seizure ) unrelated cancer unless adequately treat standard medical therapy 8 . Significant vascular disease ( e.g . aortic aneurysm require surgical repair ) ≥ 6 month prior study enrollment 9 . History hemoptysis ( ≥1/2 teaspoon bright red blood per episode ) within last 3 month 10 . Evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) 11 . Current recent ( within 10 day study drug start ) use aspirin ( &gt; 325mg daily ) , clopidogrel ( &gt; 75mg daily ) . 12 . Recent initiation full dose oral parental anticoagulant place least 2 week . 13 . Tumor invade abut major blood vessel 14 . Tumor histology classify squamous cell histology . 15 . Any history abdominal fistula GI perforation within 6 month study enrollment Pregnant lactate woman Any type systemic anticancer therapy ( chemotherapy experimental drug ) within 2 week start treatment protocol Any radiotherapy within 1 week start treatment protocol Any major surgery within 4 week start treatment protocol Any evidence clinically significant interstitial lung disease Known hypersensitivity component bevacizumab osimertinib</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Osimertinib</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>metastatic</keyword>
	<keyword>16-033</keyword>
</DOC>